Davide Tonduti1, Chiara Aiello2, Florence Renaldo3, Imen Dorboz4, Simon Saaman5, Diana Rodriguez6, Houda Fettah7, Monique Elmaleh8, Roberta Biancheri9, Sabina Barresi2, Loredana Boccone10, Simona Orcesi11, Anna Pichiecchio12, Roberta Zangaglia13, Hélène Maurey14, Andrea Rossi15, Odile Boespflug-Tanguy3, Enrico Bertini2. 1. Department of Child Neurology, Neurological Institute C. Besta Foundation IRCCS, Milan, Italy; INSERM UMR1141, Paris Diderot University, Sorbonne Paris Cité, DHU PROTECT, France. Electronic address: davidetondu@hotmail.com. 2. Unit of Neuromuscular and Neurodegenerative Disorders, Laboratory of Molecular Medicine, Bambino Gesu' Children's Research Hospital, Rome, Italy. 3. INSERM UMR1141, Paris Diderot University, Sorbonne Paris Cité, DHU PROTECT, France; AP-HP, Departement of Neuropediatrics and Metabolic Diseases, National Reference Center for Leukodystrophies, Robert Debré Hospital, Paris, France. 4. INSERM UMR1141, Paris Diderot University, Sorbonne Paris Cité, DHU PROTECT, France. 5. AP-HP, Department of Human Genetic, Molecular Biology Unit, Robert Debré Hospital, Paris, France. 6. INSERM UMR1141, Paris Diderot University, Sorbonne Paris Cité, DHU PROTECT, France; AP-HP, Department of Child Neurology, Hôpital Armand-Trousseau, GHUEP, Paris, France. 7. AP-HP, Departement of Neuropediatrics and Metabolic Diseases, National Reference Center for Leukodystrophies, Robert Debré Hospital, Paris, France; INSERM UMR1141, Paris Diderot University, Sorbonne Paris Cité, DHU PROTECT, France. 8. AP-HP, Department of Child Radiology, Paris, France. 9. Dubowitz Neuromuscular Centre, Great Ormond Street Hospital, London, UK. 10. Genetics and Rare Diseases Unit, II Division of Pediatrics, Ospedale Microcitemico, Cagliari, Italy. 11. Child Neurology and Psychiatry Unit, C. Mondino National Neurological Institute, Pavia, Italy. 12. Department of Neuroradiology, C. Mondino National Neurological Institute, Pavia, Italy. 13. Movement Disorders Unit, C. Mondino National Neurological Institute, Pavia, Italy. 14. AP-HP, Neuropediatric Departement, Reference Center for Leukodystrophies Kremlin Bicêtre Hospital, Paris, France. 15. Department of Child Neurology, Neurological Institute C. Besta Foundation IRCCS, Milan, Italy.
Abstract
BACKGROUND: Hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC) was first described in 2002. After the recent identification of TUBB4A mutation as the genetic basis of the disease, the clinical and neuroimaging phenotype related to TUBB4A mutations expanded, ranging from primary dystonia type 4 with normal MRI to severe H-ABC cases. PATIENTS AND METHODS: The study included patients referred to us for an unclassified hypomyelinating leukodystrophy. We selected patients with deleterious heterozygous TUBB4A mutations. Molecular analysis of TUBB4A was performed on genomic DNA extracted from peripheral blood. RESULTS: The series included 12 patients (5 females and 7 males). Five patients carried the common mutation c.745G > A (p.Asp249Asn), while the remaining harbored different mutations. Three new mutations were found in 5 patients. Clinical and neuroimaging observations are described. A clear correlation between the clinical presentation and the genotype seems to be absent in our group of 12 patients. CONCLUSIONS: TUBB4A-mutated patients manifest a comparable clinical and neuroimaging picture but they can differ from each other in terms of rate of disease progression. Extrapyramidal signs can be absent in the first stages of the disease, and a careful evaluation of MRI is fundamental to obtain the final diagnosis. From a therapeutic perspective a trial with l-dopa should be considered in all patients presenting extrapyramidal symptoms.
BACKGROUND:Hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC) was first described in 2002. After the recent identification of TUBB4A mutation as the genetic basis of the disease, the clinical and neuroimaging phenotype related to TUBB4A mutations expanded, ranging from primary dystonia type 4 with normal MRI to severe H-ABC cases. PATIENTS AND METHODS: The study included patients referred to us for an unclassified hypomyelinating leukodystrophy. We selected patients with deleterious heterozygous TUBB4A mutations. Molecular analysis of TUBB4A was performed on genomic DNA extracted from peripheral blood. RESULTS: The series included 12 patients (5 females and 7 males). Five patients carried the common mutation c.745G > A (p.Asp249Asn), while the remaining harbored different mutations. Three new mutations were found in 5 patients. Clinical and neuroimaging observations are described. A clear correlation between the clinical presentation and the genotype seems to be absent in our group of 12 patients. CONCLUSIONS:TUBB4A-mutated patients manifest a comparable clinical and neuroimaging picture but they can differ from each other in terms of rate of disease progression. Extrapyramidal signs can be absent in the first stages of the disease, and a careful evaluation of MRI is fundamental to obtain the final diagnosis. From a therapeutic perspective a trial with l-dopa should be considered in all patients presenting extrapyramidal symptoms.
Authors: Devesh C Pant; Imen Dorboz; Agatha Schluter; Stéphane Fourcade; Nathalie Launay; Javier Joya; Sergio Aguilera-Albesa; Maria Eugenia Yoldi; Carlos Casasnovas; Mary J Willis; Montserrat Ruiz; Dorothée Ville; Gaetan Lesca; Karine Siquier-Pernet; Isabelle Desguerre; Huifang Yan; Jingmin Wang; Margit Burmeister; Lauren Brady; Mark Tarnopolsky; Carles Cornet; Davide Rubbini; Javier Terriente; Kiely N James; Damir Musaev; Maha S Zaki; Marc C Patterson; Brendan C Lanpher; Eric W Klee; Filippo Pinto E Vairo; Elizabeth Wohler; Nara Lygia de M Sobreira; Julie S Cohen; Reza Maroofian; Hamid Galehdari; Neda Mazaheri; Gholamreza Shariati; Laurence Colleaux; Diana Rodriguez; Joseph G Gleeson; Cristina Pujades; Ali Fatemi; Odile Boespflug-Tanguy; Aurora Pujol Journal: J Clin Invest Date: 2019-02-11 Impact factor: 14.808
Authors: Filippo Arrigoni; Romina Romaniello; Denis Peruzzo; Andrea Poretti; Maria Teresa Bassi; Carlo Pierpaoli; Enza Maria Valente; Sara Nuovo; Eugen Boltshauser; Thierry André Gerard Marie Huisman; Fabio Triulzi; Renato Borgatti Journal: Eur Radiol Date: 2018-07-31 Impact factor: 5.315
Authors: Ian D Duncan; Marianna Bugiani; Abigail B Radcliff; John J Moran; Camila Lopez-Anido; Phu Duong; Benjamin K August; Nicole I Wolf; Marjo S van der Knaap; John Svaren Journal: Ann Neurol Date: 2017-05-09 Impact factor: 10.422
Authors: Kristen Park; Katelyn J Hoff; Linnea Wethekam; Nicholas Stence; Margarita Saenz; Jeffrey K Moore Journal: Front Cell Dev Biol Date: 2021-11-18
Authors: Milvia Alata; Arturo González-Vega; Valeria Piazza; Anke Kleinert-Altamirano; Carmen Cortes; Juan C Ahumada-Juárez; Jose R Eguibar; Alejandra López-Juárez; Victor H Hernandez Journal: Front Neurol Date: 2021-07-14 Impact factor: 4.003